Ingredion has announced the approval of a petition submitted to the U.S. Food and Drug Administration (FDA), resulting in a qualified health claim that will enable food manufacturers to communicate the relationship between high-amylose maize resistant starch and a reduced risk of type 2 diabetes on the packages of conventional foods.
IFT Daily News
Leave a Comment